text:
Jelly Beans. Now as a ThingLink image.
As I mentioned a bit back, I have recently discovered ThingLink and have been happily playing with my newly created account for a while today.
Here's the result of my first efforts – it's still a work in progress though.
(hover over the image and click on the buttons and icons. share freely.)
This is from an image I posted to Instagram recently.


text:
The Washington Brant Foundation supports the history and artform of waterfowl decoy carving as part of our education mission. Every year the foundation sponsors a festival and decoy carving contest called the Puget Sound Open.
895 Nevitt Road
Burlington, WA
The event and judging begins at 9 am
The 2017 Rules and Regulations brochure is available for download here: 2017 WBF Decoy Carving Contests and Rules.
You can also download copies of the entry form here: 2017 WBF Decoy Contest Entry Form
Some of the contest's we are featuring this year include:
Brant Division
Our famous Brant division contest. One of our most popular events. Compete with regional and national carvers for prizes including money and cool custom WBF embroidered Filson gear.
Open Working Decoys
Like last year, we have combined the three open class categories (Diver, Puddler, and Confidence) into one division. The best of each class will compete for the best of show title. Working decoy class rules apply.
2017 Washington State Ducks Unlimited Decoy Contest
Washington Brant Foundation will be also be host to the 2017 Washington State Ducks Unlimited Decoy Contest. Working class carving and painting restrictions do not apply to this category, allowing for a more detailed decoy.
This year's carving is a drake common merganser. 1st, 2nd, and 3rd place entries are purchase awards and will be raffled off at the Washington State Ducks Unlimited Banquet. Entry Fee is $10 per decoy. More details on here: 2017 Washington State Ducks Unlimited Contest Details
Other Puget Sound Open contests include:
- Novice and Youth Division
- Foam Division
- Miniature Decoy Swap
See the Rules and regulations brochure for full details. 2017 Brant Contests and Rules

subset: commoncrawl


text:
Opened 8 years ago
Closed 7 years ago
Last modified 7 years ago
#8132 closed defect (fixed)
CDS_Control/Browse can't process IDs containing '&' in GET requests
|Reported by:
|Kris Raney <mythtv@…>
|Owned by:
|MythTV - UPnP
|Ticket locked:
The problem is in HTTPRequest::GetParameters? - it performs substitutions on %26 and & BEFORE splitting the get request into fields. So no matter how you escape the ampersands in a program name, it always gets interpreted as a field separator.
For example, "ObjectID=RecTv?/1/key=Law%20%26%%20Order" would first get unescaped to "ObjectID=RecTv?/1/key=Law & Order", and then split up into an "ObjectID" field with a value of "RecTv?/1/key=Law " and an "Order" field.
Of course, standard UPnP would be making SOAP requests rather than GET requests, but having GET working properly is handy for testing.
Attachments (0)
Change History (8)
comment:1 Changed 8 years ago by robertm
- Owner changed from dblain to beirdo
- Status changed from new to assigned
comment:2 Changed 8 years ago by beirdo
- Status changed from assigned to accepted
I will attempt to look into this once I have recorded a file with an & in it (Rizzoli & Isles -- tomorrow).
comment:3 Changed 7 years ago by beirdo
- Milestone changed from unknown to 0.25
- Status changed from accepted to infoneeded
What is the necessity of this? As mentioned, UPnP is meant to use SOAP. This shouldn't be necessary. Please let me know what the use case is.
comment:4 Changed 7 years ago by anonymous
One general use case is for debugging. My specific use case is an attempt to make a myth client for Yahoo! widgets, which would run natively on TVs that support them. The only real option for client requests in that API is HTTP GET requests.
Since the API supports GET requests, and it's only a matter of reshuffling two lines of code so that escaping happens after the GET is broken into separate fields, instead of before, I don't see the harm.
comment:5 Changed 7 years ago by stuartm
- Milestone 0.25 deleted
Milestone 0.25 deleted
comment:6 Changed 7 years ago by robertm
- Status changed from infoneeded to assigned
comment:7 Changed 7 years ago by beirdo
- Resolution set to Fixed
- Status changed from assigned to closed
Fixed in f76028ba358 on master.
comment:8 Changed 7 years ago by Gavin Hurlbut
- Resolution changed from Fixed to fixed
Fix passing a URL key/value containing %26 (escaped &)
It seems that this code *only* deals with Parameters in the URL (maybe on POST too), but not in SOAP requests from UPnP clients. It should be a benign change to not mess with %26 in the params string before splitting on &. Any self-respecting client will know that & separates the keys, and not to escape them. If this breaks any specific clients, we will have to put in a workaround for the broken client perhaps.
Fixes #8132.
Changeset: f76028ba35811818f75c3d39faa4479b024bc846


text:
X-802R Runaway Black Helmet X-lite
product informations X-802R Runaway Black Helmet
X-Lite X-802R
X-802R is the racing helmet in composite fibers Nolangroup. In this project, the culmination of years of experience in the top levels of motorcycle racing competitions each component (shell, visor, liner, and ventilation system) is the product of innovative development, aimed at providing a product with constant quality and perfect performance. Every detail has been carefully designed considering top performance and developed along an experimental circuits on the MotoGP and SBK. Already at the beginning of the 2008 motorcycle racing season, Casey Stoner, Jorge Lorenzo, Carlos Checa, Marco Melandri and other riders sponsored by Nolangroup tested and experimented many of the innovative technical solutions found on this helmet which is now available for motorcyclists and demanding. The new visor, already introduced with the Model X-802, has a wider field of view, and a better geometry of rotation which facilitates the operation of opening or closing. In combination we find the classical and well functional system of rotation and quick release that makes it simple and easy disassembly of the visor in case of replacement. Equipped with locking aperture 4 mm, to facilitate the demisting and ventilation during the warmer months, the mechanism relies on the solution Double Action. The shell is made of lightweight composite material, and is equipped with aerodynamic appendix that ensures stability and improved ventilation. The interior triple density Unitherm2 fabric, removable and washable, complete the picture of this helmet Top of range.


text:
By Jenny Dial Creech
Guard Jeremy Lin and the Rockets will be able to catch their breath during a four-day break between games before hosting the Lakers on Wednesday.
Guard Jeremy Lin and the Rockets will be able to catch their breath...
The month of December brought challenges for the Rockets.
They went 8-8 to end 2013, playing eight games in 12 days. They struggled on defense and made just over 30 percent of their 3-point attempts. They continued to battle injuries and had issues with depth.
They started January with a win and a new attitude, but even with a schedule that allows for more practice, players coming back from injuries and almost half a season under their belts, the Rockets know January won't be easier.
The Rockets started this month with a big break between games. After their 102-100 win over the Knicks on Friday night at Toyota Center, the team took two days off and will resume practice Monday. They return to the court Wednesday night to host the Lakers - a team to which they lost Nov. 7.
The Rockets play five teams with winning records this month - Atlanta, Oklahoma City, Portland, San Antonio and Dallas. They also play Memphis, a team they have needed a fourth-quarter comeback against twice, and Sacramento, a team to which they have lost twice this season.
To read this article in one of Houston's most-spoken languages, click on the button below.
Schedule gets tougher
"We have to prepare every day for every team one at a time, understand that it's not going to get any easier," forward Chandler Parsons said. "There are really good players, good teams in this league, and we are going to get teams' best every night.
"If we are going to get where we need to get to, we have to play how we are supposed to and give our best every night."
The players said the two days of rest were needed. Thursday was the first day since training camp that the team had 12 players available for practice.
So with a couple days of rest and a couple days of practice, depth should improve.
"You have to get your work in still, but it's a good time to rest your legs," guard Aaron Brooks said. "We've got some good games coming up. It's our chance to make a move."
That move will require strong play in a tough stretch of the schedule. Parsons said the win over New York was a step in the right direction.
"We haven't been playing well lately, but we have been finding ways to win," he said. "I think our shooting is going to improve.
"When we are playing like this and it's not pretty, we have to make things easier for each other, and this is when we really have to play unselfish offensively and defensively, because it's not coming easy. We have to do little things better."
Coach Kevin McHale emphasizes defense and rebounding in practice and said the team will continue to work on its chemistry as it moves forward.
Guard James Harden said the first step to major improvement is the game Wednesday night.
Extended trip
"We have been having a lot of games, a lot of four in five nights, so it gives us time to rest our bodies and get healthy and get some good practice days in to mentally prepare ourselves for that Lakers game and the big road trip games," Harden said.
After Wednesday, the Rockets go on a four-game road trip to Atlanta, Washington, Boston and New Orleans. The time off and practice this week will help the team when it comes time to get back in the grind, Harden said.
Sports Columnist
© 2017 Hearst Newspapers, LLC.


text:
JOHANNESBURG – South African new-vehicle sales fell 12.0% to 46,248 units in February, the National Association of Automobile Manufacturers of South Africa reports. New-car deliveries slipped 14.8% to 27,505 units, compared with 32,272 prior-year. Sales of light-commercial vehicles, pickup trucks and minibuses declined 10.7% to 15,514 units, from year-ago's 17,377. Medium-truck sales rose 2.2% to 1,262 units, while heavy-truck deliveries jumped 19.8% to 1,967. New-vehicle exports ...
Premium Content (PAID Subscription Required)
"South Africa Sales Tumble in February" is part of the paid WardsAuto Premium content. You must log in with Premium credentials in order to access this article. Premium paid subscribers also gain access to:
All of WardsAuto's reliable, in-depth industry reporting and analysis
Hundreds of downloadable data tables including:
• Global sales and production data by country
• U.S. model-line inventory data
• Engine and equipment installation rates
• WardsAuto's North America Plant by Platform forecast
• Product Cycle chart
• Interrelationships among major OEMs
• Medium- and heavy-duty truck volumes
• Historical data and much more!
For WardsAuto.com pricing and subscription information please contact
Lisa Williamson by email: firstname.lastname@example.com or phone: (248) 799-2642
Current subscribers, please login or CLICK for support information.


text:
lifesize.com HD Video Conferencing Solutions & Web Conferencing Software
Lifesize provides enterprise & business-class video, audio, & web conferencing solutions, software, equipment & support. Start your free...
Keywords: high definition video, HD Video Conferencing, lifesize, lifesize communications, lifesize cloud
adam-holland.com Adam Holland — Coming Soon
Keywords: learn to play guitar, learn to play piano, Learn Music From Home, Learn music at home, learn to violin
levinassociates.com Irving Levin Associates, Inc. | Reliable and Timely Business Intelligence on M&A and Finance in Healthcare and Seniors Housing Since 1948
Irving Levin Associates--Business Intelligence on M&A and Finance in Health Care and Seniors Housing since 1948.
Keywords: senior care news, senior housing finance, health care publications, senior care investor, hospital service analysis
partystandups.com Party Standups | Life-Size Cardboard Cutouts Custom Made From Your Photo
Order Party Standups, the only custom life-size cardboard cutouts laser-cut from your photo or picture. Next-Day Rush and Free Shipping on all cutouts & standups. 25,000+ customers trust Party Standups, the only printer of laser-cut custom cardboard...
Keywords: cut out, life size cutouts, custom life size cardboard cutouts, life-size photo cutouts
lifesizephotostandups.com Life Size Custom Photo Stand Up Displays from Foamboardsource.com - LifeSize Cutouts, Photos, Foamboard, Custom Standups
Get your life size photo cutouts and stand ups. We will take any photo that you have and produce any size photo standup that you would like. The photo will be blown up to life size for your party or event or advertisement or anything else you would...
Keywords: cut out, lifesize, Custom, life size photos, life size pictures
popsalata.com POPSALATA.COM
Justin Bieber, One Direction, Rihanna, Adele, Tarkan, Justin Timberlake, Beyonce, Taylor Swift, Harry Styles, Louis Tomlinson, Zayn Malik, Adam Levine,1D, PSY, Harlem Shake, Bruno Mars, Murat Boz, Murat Dalkılıç, Sıla, Hadise, Yalın, Hande Yener,...
nbcvoicelive.com The Voice - NBC.com
Watch Mondays and Tuesdays at 8/7c. The nation's strongest vocalists compete for a recording contract, with the help of superstar coaches, on The Voice.
Keywords: voice talk, the voice official website, to use such name voice, voice game, woice talk
lifesizecustomcutouts.com Custom Life-Size Cardboard Cutouts From your Photo
Life Size Custom Cutouts, Face-Ka-Bobs and Celebrities at a Great Price! Rushes Available. Perfect for any Party Event or Promotion.
Keywords: cardboard cutouts, life size cardboard cutouts, custom cardboard cutouts, standee, cardboard cutouts custom
almostrealstandups.com Almost Real Standups - Cheap Prices, Exceptional Quality. Cardboard Cutouts & Posters
Rush Shipping available on Cardboard Cutouts, Posters, Top Quality. We always deliver on time. Superb product, and service. Check out our reviews.
Keywords: custom posters, wall posters, foam board signs, cardboard cutouts custom, posters from your phototable displays
almostbreathing.com Make Cardboard Standees and Custom Cardboard Cutouts
Almostbreathing is a Software and E-book Package to Make Amazingly Realistic Custom Cardboard Cutouts. Use Any Photo to Make a Life size Cardboard Cutouts
Keywords: Milla Jovovich, cardboard cutouts, custom cardboard cutouts, cardboard standees, custom cardboard Standees
johnnystone.com Zen Cart!, The Art of E-commerce
Zen Cart! : - Celebrities NBA MLB NCAA Soccer NHL NASCAR General Metal Signs General License Plates General Street Signs Miniature Ships More Products Character Items On Sale NFL ecommerce, open source, shop, online shopping, store
Keywords: open source, online shopping, arkansas razorbacks wind chimes, statue of liberty cardboard cutout
celebritygift.com Life Size Standees, Cardboard Cutouts, Filmcells, Film Gifts
Life Size Standees and Cardboard Cut Outs of celebrities. Film Gifts include filmcells, photographs and movie memorabilia of legendary films and tv shows.
Keywords: star wars merchandise, cardboard cutouts, Movie Photographs, Filmcells, Life Size Stanees
cardboardcutouts.com Cardboard Cutouts - life size standups - theme party and event planning | CardboardCutouts.com
CardboardCutouts.com has the largest selection of cardboard cutouts on the internet! With over 1,000 lifesize cardboard cutouts to choose from, find that perfect cardboard cutout standup for a theme party, event, birthday gift, holiday, media room,...
Related keywords for life size custom cutouts adam levinelife size kaws for sale, life size cutout of darren criss, adam levine rockabilly hair, life size cardboard tractor, life size resin classical statues, life size cardboard cutouts iron man, candyland life size cutouts, custom life size polaroid frame, adam levine tattoo significado, life size meryl streep cardboard cutout


text: On Wed, 2011-01-19 at 09:59 -0800, Dr. Jesus wrote: > On Wed, Jan 19, 2011 at 9:21 AM, T <t at of.net> wrote: > > IYHO, why focus on linear regulators? As Jonathan Foote pointed out, > > they aren't really more efficient than a simple resistor. Are they > > simpler in any sense? > > > > If you want efficiency (which IMHO is a must when powering with > > batteries) don't you need a boost or buck or other switching supply? > Sure, if I'm the one doing the design. However, there's an entire > class of people at Noisebridge who just want some power for an art > project and they're more interested in cheap and fast than efficiency. > If you have a simple switching supply you want on the poster, draw > one up! http://www.diodes.com/datasheets/ZXSC380.pdf , Figure 2. Doesn't get much simpler than that (and Tony found and posted the most simplest implementation recently): http://www.ledsales.com.au/catalog/index.php?main_page=product_info&cPath=131_132&products_id=384 Different question: How do you make an iterative optimization heuristic _stop_ when it has found an optimum? Christoph


text:
Organization in Sussex County DE and also shopping around for the finest in video production?
Janis Digital, pioneers in the film/video production field, is the only option for your Sussex County DE place of business.
Janis, the leading film/video production organization in the Northeast corridor, has been providing the finest in video production answers for the past twenty six plus years. As a main thought leader in the film/video production market, Janis offers exclusively the very finest film/video production footage, incorporates the best editors and video camera operators, whilst proudly owning a reputation that's second to none. Janis is here making Sussex County DE marketing projects come to be a practical marketing solution.
Below are actually the many distinctive kinds of video production whereby Janis Digital Media performs exceptionally well:
Corporate Videos:
Janis has decades of knowledge at delivering the best with the various kinds of corporate film/video production options. Big business video production entails everything from demonstrations, corporate aspects, Ceo messages, different marketing agendas and productions for internal use.
Local Venture Marketing:
Today, many small business owners require some type of promotion vehicle to discern their company from their competing firms. A top end high def video production is one means to state your message to the general public whilst building a favorable branding image for the business. Janis can certainly help your company with respect to all components of video production..
Music Film/Video Productions:
Janis Digital of Philadelphia also has assisted countless musicians and artists with regards to their musical film/video production ventures. Utilizing artistic and technological talent, has long been the power behind our outcomes in different music film/video productions.
Legal Videos:
There are numerous functions for film/video production within the legal marketplace. Two such applications contend with day in the life video productions and settlement brochure video productions. Day in the life video productions quite simply exhibit the issues that a victim must deal with daily. Rather related, settlement brochures are a more "in depth" production emphasizing all issues with the person's daily life along with the actual way it is affecting their family and friends.
Feature Length Films:
Making a film requires a great deal of imaginative energy and specialized traits in addition to a dedication to the time necessary to produce a great film. At Janis, the proprietor has been an element of several film projects and has well over forty years of expertise with the skill of film making.
Benevolent Organizations:
Janis has years of video production expertise doing business with many differing kinds of relief establishments like Golden Slipper and Variety Club. The staff at Janis would definitely be privileged to help on your future production.
Video Editing:
Having the best video editors in the marketplace, has been an additional element to help move Janis Digital Media to the upper echelons. Why not call us in regards to contract video editing with your raw video footage.
Looking for the very best in wedding or event videography, take a look at our related website, janis productions: wedding videography delaware
Janis Digital Media of Phila PA stands out as the brand you should keep in mind whenever thinking about an innovative film/video production to help with some element of marketing and advertising for the company. Janis covers the majority of the Northeast USA and are also anticipating your upcoming sussex county de film/video production venture.
Sussex County Delaware encompasses much of southern Delaware. There are many business enterprises in Sussex County and all should consider some form of video production.


text:
1 July 2009,
London, South Kensington
Price realised GBP 16,250
The Beatles
Approximately 800 previously unpublished candid, snap-shots, taken by several fans, various dates from 1968 onwards, the majority in photograph albums, subjects include:
-John & Yoko's Grapefruit signing at Claude Gill Bookshop, July 1971 (41 colour, 8 black & white);
-John performing with George at the Lyceum Ballroom, December 1969 (ten colour);
-individual Beatles entering & exiting several locations including Savile Row and Abbey Road Studios;
-John wearing a white suit holding Give Peace A Chance placards outside 3 Savile Row;
-John leaving 3 Savile Row holding copy of the Abbey Road L.P.;
-Individual Beatles signing autographs;
-Paul walking with Linda, including shots taken outside a cinema advertising Midnight Cowboy, and others of them leaving Columbia Records;
-Paul outside his London home;
-Ringo with Mal Evans;
-Individual Beatles in different cars, including John's white Mercedes limousine, Paul's purple mini, a white Rolls Royce, Ringo with a white mini, Paul with a convertible Rolls Royce, Paul in a New York taxi;
-Ringo on the steps of the EMI Recording Studios (Abbey Road);
-Paul with Martha his Old English sheepdog;
-Paul playing on the beach with Julian Lennon;
-Paul walking along the streets of New York with Linda;
-John walking along the streets of New York, alone and with Yoko; and
-Wings in concert;
Majority in colour -- majority 3½x3½in.(9x9cm.)
These photographs are offered for sale without copyright and other reproduction rights. The buyer must apply to the relevant parties to obtain such clearance and consents as may be necessary.
New York +1 212 636 2000
London +44 (0)20 7839 9060
Hong Kong +852 2760 1766
Shanghai +86 21 6355 1766
This collection of photographs were compiled by one obsessive fan, who actually ended up on the Apple payroll. The photos include images she took herself, and copies of photos taken by other fans, who would religiously wait outside various Beatle-related addresses in the hope of seeing, and possibly meeting, a member of the band.
Special Notice
No VAT will be charged on the hammer price, but VAT at 15% will be added to the buyer's premium which is invoiced on a VAT inclusive basis.
Our dedicated online sale of prints by the Chinese-born French artist reveals how his styles and themes evolved across five decades
Discover how we've brought to life the mysterious world of this important, early Surrealist work from 1926 — offered in London on 27 February


text:
Keep Your Comments Civil
Members of the Derry Town Council were correct when they said council meetings are their business meetings, not a meeting of the public. But that doesn't mean councilors or selectmen have the right to ignore their constituents. And it also doesn't mean that individual members should denigrate the comments of their fellows. At the July


text:
Whether an Integrated Team, or overall scope management, our team with their strong practical and hands-on background has proven experience in developing and implementing strategies and organization to suit the project drivers.
Focus : Defining and implementing key project specific structures and tools early in the project to ultimately allow technical, in-the-field, resources to operate more efficiently while giving accurate and consistent reporting to Senior Management
- Definition/Implementation of overall C&Q strategy In line with V-Cycle (including controlled leveraging) or ASTM 2500E guidelines
- Authoring of Validation Master Plan / Commissioning Master Plan I Commissioning Strategy
- Definition of Organization structure including Organization Chart
- Identification of Resource profiles and identification of same with focus on Core Team
- Development of Integrated Schedule and associated Manpower Loading
- Detailed Job Description and clear R&R and deliverables for team and eternal actors (Client, Construction)
- Cost plaming and management (in line with Client Strategy)
- Authoring / Developing (in line with existing Client Procedures or where gaps exist) of Project Specific Procedures intended to support Project operations
- Authoring / Developing (in line with existing Client Procedures or where gaps exist) of consistent reporting tools including K.P.I. and supporting Metrics
- Principle of Handover and integration of User and Maintenance teams
• HSE : Permit-To-Work (PTW)/ Lock-Out, Tag-Out (LOTO)
• Change Control Management
• Documentation Management
• Punchlist / Incident / Deviation Management
• C&Q Execution Principles (live document giving feed back to ensure execution consistency)
• Training Principle during C&Q Phase (including PSP Training Matrix)


text:
Germany will be looking for revenge when they play Italy in the semi-finals of Euro 2012, says Oliver Bierhoff.
The two teams will face each other on Thursday in a tie which will bring back memories of the Azzurri's heroic 2-0 win over Germany at their own World Cup in 2006.
"It's nice to be up against Italy again," Bierhoff, a German national team official, told the Gazzetta dello Sport. "German football has been waiting for revenge for some time.
"This time, though, we will be the favourites and today we are ahead of Italy," added the former Ascoli, Udinese and Milan striker.
"It will be a well-balanced semi-final and a beautiful one, but we are aware that we will be able to win it. Saying that, Italy boss Cesare Prandelli is working really well."
Prandelli replaced Marcello Lippi in the summer of 2010 after the reigning world champions were knocked out of the group phase at the South African World Cup.
Italy progressed into the last four last night after dominating England, but could only defeat them 4-2 on penalties.
See the latest Serie A predictions and betting tips with Eurotips.co.uk


text:
"Primero resistió la tierra..." ("Los Conquistadores," Neruda's Canto General) Torture methods comprise the noxious contraband, exported to South American dictatorships by way of a police chief from Indiana ("just a technician"). The staccato first movement hopscotches between roadblocks and conspiracies to introduce a Montevideo quaked by upheaval, a deft little symphony of cars braking and taking off and people jumping in and out of them sketches the kidnapping of the American diplomat (Yves Montand) by Tupamaro urban guerillas. The main debate, set in a subterranean garage, is between the gringo agent with his back to a wall covered with newspapers and the hooded Uruguayan revolutionaries pelting him with evidence of his involvement in the systematic excruciation of dissenting voices. Aboveground, meanwhile, manhunts, press conferences and parliament combat sessions keep swirling, the camera alternating between high-angled panning views of crowds and unsavory close-ups of government jackals. In a nation where CIA-approved industrialists puppeteer the presidency and Keystone Kops rush through the university to stomp on anthem-playing speakers, sinister euphemisms become the lingua fraca: "Traffic and communications" stand for master classes on prisoner electrocution, the formation of death squads is a "political necessity." The rebel's dilemma is ultimately between "a cruel and impotent act" and "a sign of weakness," the man with blood on his hands gets a hero's funeral (cf. Shadow of a Doubt). Throughout this purposefully frustrating Yankee-Go-Home pamphlet, Costa-Gavras compounds elements from both Z and The Confession to undercut jazzy urgency with weary melancholia in the face of the multi-headed interventionist chimera. The tentacle that's been severed promptly grows back, but so do the defiant eyes in the crowd. Chabrol has a warty riposte in Nada, though the real follow-ups might be the Pinochet coup the next year and the excuses made for "enhanced interrogation techniques" down the road. Screenplay by Franco Solinas. With Renato Salvatori, O.E. Hasse, Jacques Weber, Jean-Luc Bideau, Maurice Teynac, Yvette Etievant, Evangeline Peterson, Nemesio Antunes, Mario Montilles, and Andre Falcon.
--- Fernando F. Croce


text:
Hey Bloggers,
This isn't a huge deal so I've brought it to the off topic forum and plus you all seem intelligent also. ;) I've done a forum search and yada, yada, yada...nothing helpful.
Anyway, I've had this huge spike in my stats today, huge. Got up to go pee and well I'm at over 100 just on my homepage BUT I don't know where they are coming from, there isn't a referer listed, no search engine terms, ect... Anyone know what's up?
The blog I need help with is bats0711.wordpress.com.


text:
I haven't stayed in a Holiday Inn in a while so I was surprised by the modern spacious rooms and lobby. This one seems to be newly built. As a brand, looks like they are trying to step it up. The lobby area has a nice bar and there's also a nice indoor pool. Stayed in a couple of hotels this year thanks to my daughter's volleyball, this has been one of the better stays so far. Because there were several teenaged girls in the hotel I can confirm that the walls seemed a little thin. I could hear mumbles of conversations in the next room. Nothing that was too much of a bother for me but my daughter who was on another floor complained a little.
- Official Description (provided by the hotel):
- The Holiday Inn Indianapolis Carmel is ideally located in a park like setting in the heart of upscale Meridian Corporate Business Park and minutes away from the beautiful downtown Carmel Arts and Design District. Our unique six story design hotel is the only Holiday Inn located in the Indianapolis area. Renovated, spacious guestrooms and suites offer all the comforts of home including Holiday Inn signature bedding for a restful night sleep, microwave and refrigerator for your convenience and HDTV channels providing an array of viewing options on the 32 inch flat panel TV. Join family and colleagues for breakfast, dinner or drinks in the Terranova Bar and Grill. Take advantage of free Wi-Fi, 24 hour sundry shop and business center. To unwind from the day, take a dip in our indoor pool or whirlpool. Reenergize yourself in the fitness center. Business travelers will find our hotel conveniently located to companies within the North Meridian corridor including St. Vincent Hospital, Liberty Mutual, Delta Faucet, Teradata, Ingersoll Rand, Monster, Bridgestone Firestone, Belden, Verizon, and Thompson Technical. Take the day to enjoy attractions such as Broad Ripple, Children's Museum, Butler University, The Palladium, Lucas Oil Stadium, and Indianapolis Speedway. We are only 20 miles from Indianapolis Airport. Relax knowing you have made the right choice with Holiday Inn Indianapolis Carmel. ... more less
- Reservation Options:
- TripAdvisor is proud to partner with Booking.com, Expedia, Hotels.com, TripOnline SA, Ebookers, Evoline ltd, HotelQuickly, 5viajes2012 S.L. and getaroom.com so you can book your Holiday Inn Indianapolis North/Carmel reservations with confidence. We help millions of travellers each month to find the perfect hotel for both holiday and business trips, always with the best discounts and special offers.
- Also Known As:
- 4 Points By Sheraton Indianapolis Carmel
- Four Points By Sheraton Indianapolis Carmel Hotel Indianapolis
- Radisson Indianapolis
- Indianapolis Radisson


text:
TEL AVIV (Jan. 28)
Work was begun today on a 45-kilometer railway link between Hadera and Tel Aviv, which will provide a shorter main line rail span between Tel Aviv and Haifa than existed previously. To be constructed at an estimated cost of $6,600,000, the Tel Aviv-Haifa railroad through Hadera will run a total of 92 kilometers, as compared with the existing Tel Aviv-Haifa railroad which runs through Lydda, Kalkilya and Tulkarm and is 127 Kilometers in length.
The Israeli vessel "Atzmauth" (Independence) arrived here today from Marseilles with 2,000 Jewish immigrants.


text:
How did the modern biological cell acquire its transport system?
The inside of a present day plant or animal cell quite closely resembles a busy city. Like an urban metropolis with different districts interlinked by a traffic network, a cell has distinct compartments connected to each ...
Sep 09, 2016 in Cell & Microbiology
13 0


text:
December 19, 2012
The Virginian-Pilot reports, "As Gov. Bob McDonnell on Tuesday said the time is ripe to discuss educators being armed, one state lawmaker was forging ahead with plans to make that a reality. "'If people were armed, not just a police officer but other school officials who were trained and chose to have a weapon,' the governor said in his monthly appearance on Washington-area radio station WTOP, 'certainly there would have been an opportunity to stop aggressors coming into the schools.'"
Progressive Point: Children and their parents should feel secure in the knowledge that schools are safe places for learning. Turning schools into armed camps is not the answer. Public safety policy should follow the lead of law enforcement, not the gun manufacturers' lobby.
If more guns equaled less gun violence, America wouldn't have the highest rate of gun deaths in the industrialized world. Instead of turning teachers into armed guards, we should let them focus on teaching and learning and demand our leaders worry about keeping dangerous weapons off the streets.
Get the Facts:
Tweet it: Turning schools into armed camps is not the answer http://bit.ly/ZjqM8Z via @ProgressVA


text: Regeneron Pharmaceuticals Stock Price, News & Analysis (NASDAQ:REGN) $323.86 +8.04 (+2.55 %) (As of 02/23/2018 04:00 PM ET)Previous Close$323.86Today's Range$315.16 - $323.9052-Week Range$313.53 - $543.55Volume676,026 shsAverage Volume1.28 million shsMarket Capitalization$34.01 billionP/E Ratio31.38Dividend YieldN/ABeta1.47 Company Profile Financials Analyst Ratings Dividend History Earnings History Earnings Estimates Insider Trades Headlines SEC Filings Social Media Chart About Regeneron Pharmaceuticals (NASDAQ:REGN) Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates. Receive REGN News and Ratings via Email Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Industry Bio Therapeutic Drugs Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:REGN CUSIP75886F10 Webwww.regeneron.com Phone914-847-7000 Debt Debt-to-Equity Ratio0.11% Current Ratio3.82% Quick Ratio3.18% Price-To-Earnings Trailing P/E Ratio31.3818133544703 Forward P/E Ratio16.87 P/E Growth0.99 Sales & Book Value Annual Sales$5.87 billion Price / Sales5.94 Cash Flow$16.27 per share Price / Cash19.91 Book Value$57.05 per share Price / Book5.68 Profitability Trailing EPS$10.32 Net Income$1.20 billion Net Margins20.41% Return on Equity28.48% Return on Assets19.26% Miscellaneous Employees6,200 Outstanding Shares107,700,000 Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its quarterly earnings data on Thursday, February, 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $4.18 by $1.05. The biopharmaceutical company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company's revenue for the quarter was up 28.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.04 earnings per share. View Regeneron Pharmaceuticals' Earnings History. When will Regeneron Pharmaceuticals make its next earnings announcement? Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Regeneron Pharmaceuticals. Where is Regeneron Pharmaceuticals' stock going? Where will Regeneron Pharmaceuticals' stock price be in 2018? 25 analysts have issued 1 year price targets for Regeneron Pharmaceuticals' shares. Their predictions range from $356.00 to $593.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $455.13 in the next year. View Analyst Ratings for Regeneron Pharmaceuticals. What are Wall Street analysts saying about Regeneron Pharmaceuticals stock? Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock: 1. According to Zacks Investment Research, "Regeneron's fourth-quarter results were impressive as both earnings and sales beat estimates driven by strong Eylea sales. The potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales in 2018. The action date set by the FDA is Aug 11, 2018. The approval of new drugs like Kevzara and Dupixent provides a significant boost. Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging. Moreover, the company is also looking to expand Dupixent's label in uncontrolled asthma. Kevzara is also expected to pick up further. Even though sales of Praluent have failed to impress to date, we expect the same to gain traction as the year progresses. A potential approval of PD-1 antibody cemiplimab, in advanced cutaneous squamous cell carcinoma will further boost prospects. However, shares of the company have underperformed the industry in the last 12 months." (2/16/2018) 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent's growth than EYLEA's, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018) 3. Robert W. Baird analysts commented, "nothing to scoff at," Skorney said in his downgrade note. However, investor expectations for a strong performance has "stretched the valuation beyond what is reasonable" based on the initial launch metrics (see Skorney's track record here).In fact, investor expectation shifted from "high" in late April/May to "extraordinary" today, the analyst added. Meanwhile, buy-side analysts may have also gotten ahead of themselves in predicting Dupixent to outperform Novartis' blockbuster therapy, Cosentyx."We believe shares reflect a greater degree of optimism than is warranted," Skorney emphasized. "We continue to believe Dupixent will be a big drug, as reflected by our reiterated target price of $408." (8/8/2017) Who are some of Regeneron Pharmaceuticals' key competitors? Some companies that are related to Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Medivation (MDVN), Bioverativ (BIVV), bluebird bio (BLUE), Kite Pharma (KITE), Juno Therapeutics (JUNO), Exelixis (EXEL), Beigene (BGNE), Neurocrine Biosciences (NBIX), Shire-Nps Pharmaceuticals (NPSP), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), Array Biopharma (ARRY), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH) and Auspex Pharmaceuticals (ASPX). Who are Regeneron Pharmaceuticals' key executives? Regeneron Pharmaceuticals' management team includes the folowing people: P. Roy Vagelos M.D., Chairman of the Board (Age 87)Leonard S. Schleifer M.D., Ph.D., President, Chief Executive Officer, Director (Age 64)Robert E. Landry, Chief Financial Officer, Senior Vice President - Finance (Age 53)Daniel P. Van Plew, Executive Vice President, General Manager - Industrial Operations and Product Supply (Age 44)Neil Stahl Ph.D., Executive Vice President - Research and Development (Age 60)Joseph J. LaRosa, Senior Vice President, General Counsel, Secretary (Age 58)Michael Aberman M.D., Senior Vice President - Strategy and Investor Relation (Age 46)Marion McCourt, Senior Vice President and Head of Commercial (Age 57)Peter Powchik M.D., Senior Vice President - Clinical Development (Age 60)George D. Yancopoulos M.D., Ph.D., President and Chief Scientific Officer - Regeneron, Director (Age 57) Who owns Regeneron Pharmaceuticals stock? Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SANOFI (22.60%), BlackRock Inc. (5.60%), Sands Capital Management LLC (2.38%), Polen Capital Management LLC (1.29%), Geode Capital Management LLC (0.82%) and American Century Companies Inc. (0.82%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals. Who sold Regeneron Pharmaceuticals stock? Who is selling Regeneron Pharmaceuticals stock? Regeneron Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, TIAA CREF Investment Management LLC, BlackRock Inc., Assenagon Asset Management S.A., Sands Capital Management LLC, Teachers Advisors LLC, Old Mutual Global Investors UK Ltd. and American Century Companies Inc.. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Robert J Terifay. View Insider Buying and Selling for Regeneron Pharmaceuticals. Who bought Regeneron Pharmaceuticals stock? Who is buying Regeneron Pharmaceuticals stock? Regeneron Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Two Sigma Advisers LP, HealthCor Management L.P., Millennium Management LLC, UBS Asset Management Americas Inc., Bank of Montreal Can, ADAMCAPITAL Gestao de Recursos Ltda. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals. How do I buy Regeneron Pharmaceuticals stock? Shares of Regeneron Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Regeneron Pharmaceuticals' stock price today? One share of Regeneron Pharmaceuticals stock can currently be purchased for approximately $323.86. How big of a company is Regeneron Pharmaceuticals? Regeneron Pharmaceuticals has a market capitalization of $34.01 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $10.32 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe. How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected] MarketBeat Community Rating for Regeneron Pharmaceuticals (REGN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 1,023 (Vote Outperform)Underperform Votes: 807 (Vote Underperform)Total Votes: 1,830MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days. Analyst Ratings Regeneron Pharmaceuticals (NASDAQ:REGN) Analysts' Consensus Rating (How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.Today30 Days Ago90 Days Ago180 Days AgoConsensus Rating: HoldHoldHoldHoldConsensus Rating Score: 2.322.362.382.40Ratings Breakdown: 1 Sell Rating(s)15 Hold Rating(s)9 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)14 Hold Rating(s)10 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)14 Hold Rating(s)11 Buy Rating(s)0 Strong Buy Rating(s)1 Sell Rating(s)13 Hold Rating(s)11 Buy Rating(s)0 Strong Buy Rating(s)Consensus Price Target: $455.13$471.39$475.22$497.55Price Target Upside: 40.89% upside23.49% upside23.48% upside3.95% upsideRegeneron Pharmaceuticals (NASDAQ:REGN) Consensus Price Target History Regeneron Pharmaceuticals (NASDAQ:REGN) Analyst Ratings History Show: Only the Most Recent Rating From Each Brokerage All Ratings For This Stock DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails2/21/2018Canaccord GenuityDowngradeBuy -> Hold$522.00 -> $356.00Medium2/13/2018BTIG ResearchReiterated RatingHoldHigh2/9/2018SunTrust BanksSet Price TargetHold$430.00Low2/9/2018Morgan StanleyBoost Price TargetEqual Weight -> Equal Weight$401.00 -> $415.00High2/9/2018Leerink SwannLower Price TargetOutperform -> Outperform$568.00 -> $502.00High2/9/2018Robert W. BairdUpgradeNeutral -> OutperformHigh2/9/2018GuggenheimSet Price TargetBuy$530.00High2/8/2018Jefferies GroupReiterated RatingNeutral -> Hold$380.00High2/8/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$398.00 -> $444.00Low2/7/2018Credit Suisse GroupSet Price TargetBuy$440.00High2/7/2018CowenReiterated RatingHold$450.00High1/24/2018JPMorgan Chase & Co.Boost Price TargetNeutral -> Neutral$455.00 -> $457.00Low1/9/2018CitigroupReiterated RatingNeutral -> Neutral$380.00 -> $388.00High12/28/2017ArgusLower Price TargetPositive -> Buy$540.00 -> $470.00Low12/14/2017Royal Bank of CanadaReiterated RatingHold$430.00Low12/12/2017Deutsche BankInitiated CoverageHold$397.00Medium11/16/2017Evercore ISILower Price TargetOutperform$605.00 -> $445.00N/A11/13/2017Piper Jaffray CompaniesReiterated RatingBuy$540.00N/A10/20/2017BarclaysDowngradeEqual Weight -> Underweight$450.00 -> $395.00N/A9/27/2017OppenheimerReiterated RatingHoldLow9/6/2017Raymond James FinancialReiterated RatingOutperform -> Outperform$566.00Low8/9/2017Goldman Sachs GroupReiterated RatingNeutral$469.00 -> $472.00Low7/21/2017Bank of AmericaReiterated RatingBuy$589.00 -> $593.00Low6/26/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$410.00 -> $480.00Low3/17/2017CIBCInitiated CoverageMarket Perform -> Market PerformLow1/10/2017Wells Fargo & CoReiterated RatingMarket PerformN/A1/6/2017Chardan CapitalLower Price TargetNeutral$350.00 -> $345.00N/A10/28/2016Roth CapitalSet Price TargetBuy$520.00N/A8/5/2016Brean CapitalReiterated RatingBuy$489.00N/A3/15/2016GabelliInitiated CoverageBuy$574.00N/A(Data available from 2/24/2016 forward) Earnings Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings History and Estimates ChartRegeneron Pharmaceuticals (NASDAQ REGN) Earnings History by QuarterDateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails5/2/2018$4.17N/A2/8/2018Q4 2017$4.18$5.23$1.50 billion$1.58 billionViewN/A11/8/2017Q3 2017$3.83$3.99$1.45 billion$1.50 billionViewN/A8/3/2017Q2 2017$2.67$4.17$1.36 billion$1.47 billionViewListen5/4/2017Q1 2017$2.50$2.92$1.30 billion$1.32 billionViewListen2/9/2017Q4 2016$3.03$3.04$1.30 billion$1.23 billionViewListen11/4/2016Q316$2.73$3.13$1.29 billion$1.22 billionViewN/A8/4/2016Q216$2.65$2.82$1.24 billion$1.21 billionViewN/A5/5/2016Q116$2.58$2.57$1.18 billion$1.20 billionViewN/A2/9/2016Q415$3.40$2.83$1.17 billion$1.10 billionViewListen11/4/2015Q315$2.62$3.47$1.05 billion$1.14 billionViewListen8/4/2015Q215$2.77$2.89$887.03 million$999.00 millionViewListen5/7/2015Q115$2.50$2.88$820.30 million$870.00 millionViewN/A2/10/2015Q414$2.78$2.79$775.42 million$802.00 millionViewN/A11/4/2014Q314$2.57$2.52$733.04 million$726.00 millionViewN/A8/5/2014Q214$2.30$2.47$647.99 million$666.00 millionViewN/A5/8/2014Q114$0.94$0.58$609.04 million$626.00 millionViewN/A2/11/2014Q413$0.97$2.24$579.17 million$610.00 millionViewN/A11/5/2013Q313$0.92$2.40$501.93 million$597.00 millionViewN/A8/6/2013Q2 2013$0.92$1.73$470.63 million$458.00 millionViewN/A5/3/2013Q1 2013$1.46$1.78$424.26 million$440.00 millionViewN/A2/14/2013Q4 2012$1.11$1.47$392.64 million$415.00 millionViewN/A10/24/2012$1.14$1.89ViewN/A7/25/2012$0.45$0.90ViewN/A4/26/2012($0.33)$0.37ViewN/A2/13/2012($0.60)($0.37)ViewN/A10/27/2011Q3 2011($0.75)($0.68)ViewN/A7/28/2011($0.40)($0.69)ViewN/A5/3/2011Q1 2011($0.38)($0.49)ViewN/A2/17/2011Q4 2010($0.32)($0.17)ViewN/A10/28/2010Q3 2010($0.34)($0.41)ViewN/A7/28/2010Q2 2010($0.38)($0.31)ViewN/A4/29/2010Q1 2010($0.49)($0.38)ViewN/A2/18/2010Q4 2009($0.34)($0.46)ViewN/A11/3/2009Q3 2009($0.23)($0.01)ViewN/A8/4/2009Q2 2009($0.28)($0.19)ViewN/A4/30/2009Q1 2009($0.29)($0.22)ViewN/A2/26/2009Q4 2008($0.30)($0.40)ViewN/A11/4/2008Q3 2008($0.32)($0.27)ViewN/A7/31/2008Q2 2008($0.35)($0.22)ViewN/A5/1/2008Q1 2008($0.34)($0.15)ViewN/A2/27/2008Q4 2007($0.46)($0.19)ViewN/A(Earnings results data provided by Zacks Investment Research) Estimates Regeneron Pharmaceuticals (NASDAQ:REGN) Earnings EstimatesCurrent Year EPS Consensus Estimate: $19.2 EPSNext Year EPS Consensus Estimate: $20.07 EPS Dividends Dividend History for Regeneron Pharmaceuticals (NASDAQ:REGN)No dividend announcements for this company have been tracked by MarketBeat.com Insider Trades Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trading and Institutional Ownership HistoryInsider Ownership Percentage: 10.80%Institutional Ownership Percentage: 64.67%Regeneron Pharmaceuticals (NASDAQ REGN) Insider Trades by QuarterTransaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails2/9/2018Joseph L GoldsteinDirectorSell1,000$325.60$325,600.00 10/5/2017Michael S BrownDirectorSell1,500$475.00$712,500.00 9/29/2017Charles A BakerDirectorSell2,000$450.00$900,000.0011,000 9/6/2017Robert E LandrySVPSell663$498.60$330,571.8010,099 9/5/2017Robert E LandryCFOSell189$501.06$94,700.3410,099 8/31/2017Robert E LandrySVPSell427$493.43$210,694.619,099 8/25/2017SanofiMajor ShareholderBuy72,378$481.36$34,839,874.08 8/24/2017SanofiMajor ShareholderBuy166,415$480.93$80,033,965.95 8/23/2017Robert E LandrySVPSell468$476.45$222,978.609,099 8/22/2017P Roy VagelosChairmanSell56,213$474.48$26,671,944.24363,638 8/18/2017P Roy VagelosChairmanSell15,191$470.15$7,142,048.65329,543 8/17/2017P Roy VagelosChairmanSell1,305$470.00$613,350.00329,543 8/16/2017P Roy VagelosChairmanSell10,986$470.17$5,165,287.62329,543 8/8/2017Robert E LandrySVPSell526$472.19$248,371.949,099 6/22/2017Michael S AbermanSVPSell2,269$532.42$1,208,060.989,193 6/22/2017Neil StahlEVPSell8,306$532.55$4,423,360.3043,950 6/20/2017Michael S BrownDirectorSell3,000$500.00$1,500,000.003,000 6/16/2017Robert J TerifayEVPSell21,147$468.19$9,900,813.9372,043 6/15/2017Neil StahlEVPSell8,567$468.45$4,013,211.1544,245 6/9/2017Joseph L GoldsteinDirectorSell1,000$482.55$482,550.0014,000 6/2/2017Neil StahlEVPSell2,812$479.49$1,348,325.8828,477 6/2/2017SanofiMajor ShareholderBuy136,050$478.17$65,055,028.50 5/25/2017P Roy VagelosChairmanSell9,295$458.14$4,258,411.30414,156 5/12/2017Michael S BrownDirectorSell3,000$450.00$1,350,000.003,000 3/29/2017Michael S BrownDirectorSell1,000$400.00$400,000.001,000 1/11/2017SanofiMajor ShareholderBuy87,298$369.71$32,274,943.58 12/12/2016Charles A BakerDirectorSell3,000$392.02$1,176,060.0012,000 11/15/2016Arthur F RyanDirectorSell2,000$429.34$858,680.0036,500 11/14/2016Joseph L GoldsteinDirectorSell2,125$450.00$956,250.0015,125 7/29/2016Joseph L GoldsteinDirectorSell2,125$425.00$903,125.0015,125 6/14/2016SanofiMajor ShareholderBuy64,731$363.86$23,553,021.66 5/24/2016Arthur F RyanDirectorSell1,000$396.64$396,640.0040,500 5/18/2016Plew Daniel P VanEVPSell4,413$385.77$1,702,403.0111,381 4/6/2016Joseph L GoldsteinDirectorSell2,000$425.00$850,000.0013,000 3/21/2016Joseph L GoldsteinDirectorSell2,000$375.00$750,000.0016,000 2/17/2016SanofiMajor ShareholderBuy161,157$392.46$63,247,676.22 1/12/2016SanofiMajor ShareholderBuy83,938$465.04$39,034,527.52 12/29/2015Douglas S. MccorkleVPSell3,954$552.08$2,182,924.326,866 12/10/2015Michael S. BrownDirectorSell3,000$546.45$1,639,350.00 12/2/2015George YancopoulosinsiderSell43,348$549.03$23,799,352.44500,000 11/18/2015P Roy VagelosChairmanSell17,240$587.90$10,135,396.00332,880 11/10/2015Plew Daniel P. VanSVPSell5,123$554.85$2,842,496.55 11/9/2015Neil StahlEVPSell42,101$561.45$23,637,606.4522,029 11/3/2015P Roy VagelosChairmanSell17,242$580.19$10,003,635.98351,851 11/2/2015George YancopoulosinsiderSell43,348$571.61$24,778,150.28543,348 10/6/2015SanofiMajor ShareholderBuy80,538$459.71$37,024,123.98 9/23/2015SanofiMajor ShareholderBuy147,209$534.67$78,708,236.03 9/21/2015Michael S. BrownDirectorSell3,000$551.55$1,654,650.00 9/17/2015Charles A. BakerDirectorSell5,000$550.00$2,750,000.009,000 8/14/2015Peter PowchikSVPSell23,485$573.38$13,465,829.30 7/15/2015Joseph L GoldsteinDirectorSell2,000$550.00$1,100,000.00 6/22/2015Joseph L GoldsteinDirectorSell2,000$526.85$1,053,700.00 5/27/2015Robert Alexander IngramDirectorSell1,379$513.39$707,964.81 5/26/2015Plew Daniel P VanSVPSell18,370$508.42$9,339,675.40 5/22/2015Douglas S MccorkleVPSell13,000$515.60$6,702,800.00 5/22/2015Joseph L GoldsteinDirectorSell4,000$514.28$2,057,120.00 5/15/2015Michael S BrownDirectorSell5,000$495.00$2,475,000.00 3/25/2015Charles A BakerDirectorSell5,000$454.96$2,274,800.00 3/24/2015Michael S AbermanSVPSell4,843$478.99$2,319,748.57 3/18/2015Michael S AbermanSVPSell3,442$465.00$1,600,530.00 3/17/2015Robert J TerifaySVPSell10,993$451.01$4,957,952.93 3/16/2015Joseph J LarosaSVPSell18,311$450.00$8,239,950.00 2/27/2015Douglas S MccorkleVPSell3,000$416.24$1,248,720.00 2/26/2015Marc Tessier-LavigneDirectorSell3,000$421.95$1,265,850.00 2/24/2015Robert J TerifaySVPSell11,173$423.67$4,733,664.91 2/23/2015Plew Daniel P VanSVPSell9,431$427.82$4,034,770.42 2/20/2015Joseph L GoldsteinDirectorSell5,000$423.65$2,118,250.00 2/17/2015Michael S AbermanSVPSell3,692$404.46$1,493,266.32 1/2/2015Leonard S SchleiferCEOSell1,500$410.58$615,870.00 1/2/2015Peter PowchikSVPSell10,822$414.08$4,481,173.76 12/24/2014SanofiMajor ShareholderBuy201,459$393.21$79,215,693.39 12/16/2014Douglas S MccorkleVPSell8,486$410.15$3,480,532.90 11/24/2014Alfred G GilmanDirectorSell40,000$408.44$16,337,600.00 11/24/2014Neil StahlSVPSell5,307$412.93$2,191,419.51 11/18/2014Robert J TerifaySVPSell22,362$405.79$9,074,275.98 11/13/2014Plew Daniel P VanSVPSell8,575$399.34$3,424,340.50 11/12/2014Joseph L GoldsteinDirectorSell5,000$398.31$1,991,550.00 11/12/2014Leonard S SchleiferCEOSell45,817$400.30$18,340,545.10 10/28/2014Leonard S SchleiferCEOSell69,112$404.01$27,921,939.12 10/24/2014Michael S BrownDirectorSell5,000$399.00$1,995,000.00 10/24/2014Murray A GoldbergSVPSell26,788$400.70$10,733,951.60 9/16/2014SanofiMajor ShareholderBuy31,717$349.26$11,077,479.42 9/15/2014SanofiMajor ShareholderBuy140,632$345.15$48,539,134.80 9/10/2014P Roy VagelosChairmanSell10,328$350.07$3,615,522.96 8/27/2014Joseph L GoldsteinDirectorSell2,000$350.31$700,620.00 8/19/2014Michael S AbermanVPSell3,611$350.00$1,263,850.00 8/18/2014Douglas S MccorkleVPSell5,875$353.00$2,073,875.00 8/15/2014Michael S BrownDirectorSell3,000$349.20$1,047,600.00 8/14/2014Joseph L GoldsteinDirectorSell2,000$347.65$695,300.00 8/13/2014P Roy VagelosChairmanSell8,028$340.01$2,729,600.28 8/11/2014Neil StahlSVPSell11,646$339.96$3,959,174.16 8/11/2014P Roy VagelosChairmanSell11,972$340.11$4,071,796.92 8/8/2014Neil StahlSVPSell2,841$340.60$967,644.60 8/7/2014Plew Daniel P VanSVPSell6,806$338.37$2,302,946.22 8/6/2014Joseph L GoldsteinDirectorSell2,000$331.20$662,400.00 7/15/2014SanofiMajor ShareholderBuy129,100$314.92$40,656,172.00 7/14/2014SanofiMajor ShareholderBuy300,000$316.80$95,040,000.00 7/10/2014SanofiMajor ShareholderBuy175,000$311.08$54,439,000.00 7/9/2014SanofiMajor ShareholderBuy348,000$309.76$107,796,480.00 7/7/2014SanofiMajor ShareholderBuy356,700$312.37$111,422,379.00 7/2/2014SanofiMajor ShareholderBuy212,400$307.25$65,259,900.00 7/1/2014SanofiMajor ShareholderBuy212,400$300.20$63,762,480.00 6/30/2014SanofiMajor ShareholderBuy262,400$281.17$73,779,008.00 5/23/2014Plew Daniel VanSVPSell5,369$295.93$1,588,848.1715,441 5/19/2014Sanofimajor shareholderBuy190,751$300.04$57,232,930.04 3/28/2014Sanofimajor shareholderBuy306,945$306.73$94,149,239.85 3/27/2014Sanofimajor shareholderBuy306,945$311.01$95,462,964.45 3/24/2014Charles BakerDirectorSell15,000$302.67$4,540,050.009,000 3/24/2014Sanofimajor shareholderBuy306,945$307.91$94,511,434.95 3/21/2014Sanofimajor shareholderBuy305,115$321.22$98,009,040.30 3/20/2014Sanofimajor shareholderBuy67,703$328.33$22,228,925.99 3/17/2014Michael BrownDirectorSell2,000$334.29$668,580.0014,662 3/17/2014Sanofimajor shareholderBuy115,711$328.46$38,006,435.06 3/12/2014Sanofimajor shareholderBuy220,995$334.69$73,964,816.55 3/11/2014Sanofimajor shareholderBuy380,532$330.41$125,731,578.12 3/7/2014Sanofimajor shareholderBuy150,277$328.72$49,399,055.44 3/3/2014Sanofimajor shareholderBuy251,594$338.12$85,068,963.28 2/27/2014Michael BrownDirectorSell1,000$335.00$335,000.0014,662 2/25/2014Joseph GoldsteinDirectorSell1,000$338.86$338,860.00 2/25/2014Murray GoldbergSVPSell11,871$339.55$4,030,798.0563,102 2/21/2014Alfred GilmanDirectorSell5,000$340.00$1,700,000.00 2/21/2014Murray GoldbergSVPSell21,258$336.51$7,153,529.5863,102 2/20/2014Joseph GoldsteinDirectorSell1,000$326.99$326,990.001,000 2/18/2014Michael AbermanVPSell3,648$331.42$1,209,020.1615,600 2/18/2014Robert TerifaySVPSell12,865$332.68$4,279,928.2020,029 2/13/2014Neil StahlSVPSell22,612$318.82$7,209,157.8424,391 2/12/2014George YancopoulosInsiderSell88,987$320.33$28,505,205.711,068,343 2/12/2014Joseph GoldsteinDirectorSell1,000$320.62$320,620.002,000 2/11/2014Alfred GilmanDirectorSell5,000$320.00$1,600,000.00 2/11/2014Douglas MccorkleVPSell5,819$325.00$1,891,175.00 2/11/2014P Roy VagelosChairmanSell11,475$325.10$3,730,522.5069,960 2/7/2014Sanofimajor shareholderBuy168,511$286.78$48,325,584.58 2/5/2014Sanofimajor shareholderBuy397,264$284.12$112,870,647.68 2/3/2014Sanofimajor shareholderBuy208,972$283.78$59,302,074.16 1/28/2014Sanofimajor shareholderBuy157,920$275.90$43,570,128.00 1/14/2014Alfred GilmanDirectorSell5,000$300.00$1,500,000.00 1/14/2014Douglas MccorkleVPSell4,000$290.00$1,160,000.00 1/2/2014Peter PowchikSVPSell20,668$274.77$5,678,946.3625,447 12/20/2013Peter PowchikSVPSell9,133$270.21$2,467,827.9320,742 11/26/2013George SingDirectorSell10,000$295.00$2,950,000.00112,772 11/6/2013Joseph GoldsteinDirectorSell1,000$300.74$300,740.003,000 9/19/2013Leonard SchleiferCEOSell102,949$302.67$31,159,573.8342,087 9/19/2013P Roy VagelosChairmanSell145,356$302.86$44,022,518.1665,759 9/18/2013Plew Daniel VanSVPSell23,977$303.17$7,269,107.0910,736 9/18/2013William RobertsVPSell15,000$304.00$4,560,000.0016,644 9/9/2013Leonard S SchleiferCEOSell5,000$275.47$1,377,350.00 8/23/2013Joseph GoldsteinDirectorSell1,000$238.29$238,290.004,000 6/10/2013Charles A BakerDirectorSell15,000$251.84$3,777,600.00 5/31/2013Arthur F RyanDirectorSell2,500$249.55$623,875.00 5/28/2013Joseph L GoldsteinDirectorSell4,000$252.20$1,008,800.00 5/21/2013Murray A GoldbergCFOSell66,835$259.74$17,359,722.90 5/17/2013Michael S BrownDirectorSell15,000$275.19$4,127,850.00 5/14/2013Michael S AbermanVPSell5,529$279.61$1,545,963.69 5/13/2013Neil StahlSVPSell23,038$276.88$6,378,761.44 5/10/2013George L SingDirectorSell5,000$270.00$1,350,000.00 5/8/2013Robert J TerifaySVPSell8,231$261.23$2,150,184.13 5/6/2013P Roy VagelosChairmanSell12,018$263.15$3,162,536.70 11/27/2012P Roy VagelosChairmanSell64,753$175.22$11,346,020.66 11/26/2012Charles A BakerDirectorSell15,000$173.87$2,608,050.00 11/14/2012Michael S BrownDirectorSell7,000$147.03$1,029,210.00 11/1/2012Arthur F RyanDirectorSell10,000$145.57$1,455,700.00 9/6/2012Charles A BakerDirectorSell15,000$150.00$2,250,000.00 8/23/2012George L SingDirectorSell10,000$140.50$1,405,000.00 (Data available from 1/1/2013 forward) Headlines Regeneron Pharmaceuticals (NASDAQ REGN) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineSome Thoughts On The Continued Negative Media For Regeneron - Seeking Alphaseekingalpha.com - February 23 at 3:44 PMCorcept's (CORT) Earnings and Sales Meet Estimates in Q4finance.yahoo.com - February 23 at 10:45 AMTaking Stock of Regeneron Pharmaceuticals' Marketed Productsfinance.yahoo.com - February 22 at 3:47 PMRegeneron Pharmaceuticals' Kevzara, Arcalyst, and Zaltrapfinance.yahoo.com - February 22 at 3:47 PMAnalyst Ratings for Regeneron Pharmaceuticals and Its Peersfinance.yahoo.com - February 22 at 3:47 PMA Look at Regeneron Pharmaceuticals' Product Pipelinefinance.yahoo.com - February 22 at 3:47 PMRegeneron Pharmaceuticals and Its Financial Performancefinance.yahoo.com - February 22 at 3:47 PMBenzinga's Top Upgrades, Downgrades For February 21, 2018 - Benzingawww.benzinga.com - February 21 at 3:46 PMRegeneron's Eylea Has Mysterious Rise in Side Effect Reportsfinance.yahoo.com - February 21 at 11:24 AMRegeneron shares slip after Canaccord downgrades stock, slashes price target 32%finance.yahoo.com - February 21 at 11:24 AMNovavax (NVAX) in Focus: Stock Moves 8.3% Higherfinance.yahoo.com - February 20 at 9:56 AMRegeneron Annual Report, Earnings Forecast And Stock Valuationseekingalpha.com - February 19 at 9:56 AMZacks: Brokerages Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Announce Quarterly Sales of $1.54 Billionwww.americanbankingnews.com - February 18 at 2:54 AM$4.50 Earnings Per Share Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarterwww.americanbankingnews.com - February 16 at 5:10 PMRegeneron Pharmaceuticals (REGN) Rating Increased to Strong-Buy at Zacks Investment Researchwww.americanbankingnews.com - February 16 at 10:12 AMThe Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugsfinance.yahoo.com - February 15 at 3:46 PMRegeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercialfinance.yahoo.com - February 14 at 3:21 PMRegeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of "Hold" from Brokerageswww.americanbankingnews.com - February 13 at 7:30 PMRegeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in Stockwww.americanbankingnews.com - February 13 at 6:28 PM3 Biotech Stocks Facing Steep Declinesfinance.yahoo.com - February 13 at 3:18 PMStocks Up, These Groups Smoke Indexes; Buy This Bitcoin Fund Or Wait?finance.yahoo.com - February 13 at 3:18 PMBTIG Research Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)www.americanbankingnews.com - February 13 at 11:32 AMHandling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)finance.yahoo.com - February 13 at 5:51 AMRegeneron - Levels To Regenerate? - Seeking Alphaseekingalpha.com - February 11 at 3:22 PMRegeneron Pharmaceuticals (REGN) PT Set at $530.00 by Guggenheimwww.americanbankingnews.com - February 11 at 12:42 AMRegeneron Pharmaceuticals (REGN) Upgraded by Robert W. Baird to Outperformwww.americanbankingnews.com - February 10 at 10:54 PMShould You Expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) To Continue Delivering An ROE Of 24.25%?finance.yahoo.com - February 10 at 5:46 AMLeerink Swann Trims Regeneron Pharmaceuticals (REGN) Target Price to $502.00www.americanbankingnews.com - February 9 at 10:36 PMRegeneron Pharmaceuticals (REGN) Price Target Raised to $415.00www.americanbankingnews.com - February 9 at 6:10 PMRegeneron Pharmaceuticals (REGN) PT Set at $430.00 by SunTrust Bankswww.americanbankingnews.com - February 9 at 4:38 PMUpdating The Bullish Case For Regeneron As The Stock Drops - Seeking Alphaseekingalpha.com - February 9 at 3:24 PMAnalyst: Regeneron Is Undervalued By The Streetfinance.yahoo.com - February 9 at 3:24 PMCommit To Buy Regeneron Pharmaceuticals At $200, Earn 4.5% Using Options - Nasdaqwww.nasdaq.com - February 9 at 5:49 AMRegeneron Pharmaceuticals' (REGN) "Hold" Rating Reaffirmed at Jefferies Groupwww.americanbankingnews.com - February 8 at 8:22 PMRegeneron Pharmaceuticals (REGN) Given a $440.00 Price Target at Credit Suisse Groupwww.americanbankingnews.com - February 8 at 7:48 PMBMO Capital Markets Reaffirms "Hold" Rating for Regeneron Pharmaceuticals (REGN)www.americanbankingnews.com - February 8 at 4:56 PMRegeneron Pharmaceuticals (REGN) Lowered to Neutral at BTIG Researchwww.americanbankingnews.com - February 8 at 4:22 PMRegeneron posts 31 percent drop in quarterly profit - Reuterswww.reuters.com - February 8 at 3:18 PMRegeneron Pharmaceuticals Q4 Income Rises - Nasdaq.com - Nasdaqwww.nasdaq.com - February 8 at 3:18 PMRegeneron Pharmaceuticals (REGN) Q4 2017 Results - Earnings Call Transcript - Seeking Alphaseekingalpha.com - February 8 at 3:18 PMRegeneron (REGN) Tops Q4 Earnings & Salesfinance.yahoo.com - February 8 at 3:18 PMRegeneron CEO says fears over Eylea "greatly exaggerated"finance.yahoo.com - February 8 at 3:18 PMRegeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Growfinance.yahoo.com - February 8 at 3:18 PMRegeneron Dips In Sympathy With Biotechs Despite Quarterly Beatfinance.yahoo.com - February 8 at 3:18 PMAmgen's Repatha and Blincyto: How They Did in 3Q17finance.yahoo.com - February 8 at 3:18 PMRegeneron Pharmaceuticals (REGN) Issues Quarterly Earnings Resultswww.americanbankingnews.com - February 8 at 11:16 AMSanofi, Regeneron Dip As Eczema Drug Dupixent Lags In Europefinance.yahoo.com - February 8 at 5:28 AMSanofi (SNY) Q4 2017 Earnings Conference Call Transcriptfinance.yahoo.com - February 8 at 5:28 AMRegeneron Pharmaceuticals (REGN) Rating Reiterated by Canaccord Genuitywww.americanbankingnews.com - February 8 at 12:14 AMRegeneron Pharmaceuticals (REGN) Given Hold Rating at Cowenwww.americanbankingnews.com - February 8 at 12:14 AM SEC Filings Regeneron Pharmaceuticals (NASDAQ:REGN) SEC Filings This page is loading this company's SEC Filings. Please wait... Social Media Financials Regeneron Pharmaceuticals (NASDAQ:REGN) Income Statement, Balance Sheet and Cash Flow Statement Chart Regeneron Pharmaceuticals (NASDAQ REGN) Stock Chart for Saturday, February, 24, 2018Loading chart… This page was last updated on 2/24/2018 by MarketBeat.com Staff


text:
Perfect for social media campaigns and blogs. Web photos (up to .5 MP). 1 Seat.
Learn More
Build a high res library or promote your brand. Up to Large (2.5-4.5 MP). 5 Seats.
Learn More
Get more high res photos and more. Up to Large (2.5-4.5 MP). 25 Seats.
Learn More
yellow, field, tent, green, grassy, collapsible, shelter
yellow collapsible tent on green grassy field


text:
- Home >
- Accessories >
- Machinery Accessories >
- General Machinery Accessories >
- Bases >
- Axminster Trade Series Planer Thicknesser Mobile Base
This heavy duty mobile machine base with its two fixed and two castoring wheels has been especially made to fit the Axminster Trade Series AT107PT and AT129PT planer thicknessers, resulting in mobility around the workshop. Once the machine is positioned, the castoring front wheels can be raised with the screw-in feet to allow the base to rest securely on the floor. Maximum total load is 450kg and the size limits are 490 x 580mm minimum, up to 670 x 820mm maximum. Very well made and easy to use.
Own it? Review it! Be the first to tell everyone what you think about this product...


text:
Veteran New York Times columnist explains why he chose to write about the president for his debut piece with New York Magazine.
Columnist Frank Rich
Tavis: Always pleased to welcome Frank Rich back to this program. After more than 30 years with "The New York Times," both as theater critic and, of course, opinion columnist, he makes his debut this week as writer-at-large for "New York" magazine. His first piece is called "Something Rotten: Obama's Failure to Right the Wrongs of this Crash Has Haunted His Presidency and Could Undo It." Frank Rich joins us tonight from New York. Frank, always good to have you on this program, sir.
Frank Rich: Great to be with you, Tavis, as always.
Tavis: Well, I am glad, as many others are, your fans, glad to have you back and looking forward to digging into what you have to say in the coming months and years inside "New York" magazine. Let me start with the obvious. Why this particular piece about Obama as your debut?
Rich: I guess as I was looking at various subjects, what really grabbed me and pushed me in this direction was the fact that Mitt Romney, a guy who is associated with corporate America, whose career was mainly in leveraged buyouts that often threw American workers out of work, that he is getting way with presenting himself as sort of a working-class hero, appearing in front of deserted factories and as a sort of nouvelle FDR.
I thought how could Romney, of all people, get away with this post, and I realized a lot of it has to do with the vacuum that Barack Obama has left in terms of his economic record as president.
Tavis: Is there a parallel? I'll come back to Obama and Romney in a moment. Is there a parallel, though, to how George Bush got away with demonizing John Kerry when Kerry served and Bush didn't?
Rich: That's the exact parallel, only in this particular case – in that case, Kerry, his record was exemplary. He had done nothing to deserve it. There's just enough that's wanting in the Obama record so far that he gave Romney a slight opening for his exaggerations and caricatures.
Tavis: So you've got a lot of words here to unpack this in the new piece, which I've read, but to your mind, what is it that Obama has not done that's led to this failure of writing the wrongs specifically about the crash?
Rich: Well, there's several things. The two biggest things are first of all no one who gamed the system that created the circumstances for this crash has been punished. Low-level con people have, Bernie Madoff has, but the people who game the whole housing bubble didn't.
In fact, quite the contrary, they took their fortunes and left while the rest of America was left holding the bag. So that's a failure of law enforcement, to my mind, particularly given that Obama pledged to do that – in fact, started a task force within the Justice Department called "Operation Broken Trust," but it has never had any significant prosecutions or even as far as one can tell real serious investigations of what went down.
The second thing is a failure to reform Wall Street. The Dodd-Frank bill was not great to begin with and now is of course at sea because of poorly staffed agencies that have to implement the rules that are being besieged by lobbyists, by the way, both on the Democratic and Republican side. Obama failed to fight for Elizabeth Warren or even appoint her in the consumer protection agency he set up.
I'll tell you the third thing that's unfortunate is that his record on jobs, while hardly worthless and indeed the stimulus, even if it was too small, saved several million jobs, has never been the full focus of this administration. So you get the feeling, it sort of gives the image of favoring the corporate status quo on Wall Street, even if that's not what in his heart of hearts he believes.
Tavis: That third one may be just enough of an albatross to make sure he doesn't get reelected alone – that is to say, not having done enough on the jobs issue. But as I listen to you lay out your framework, the first two Obama could very well argue he didn't control. By your own admission, the first was about law enforcement and the second – my words, not yours – is really about Congress, not necessarily the White House. That Dodd-Frank bill had a whole lot of politicking that went along with it.
It's the third one that could mess him up. But what say you about the fact that when he gets on the campaign trail he can eschew responsibility for the first two, can he not?
Rich: Up to a point. The fact is that he is not – the law enforcement part of it has been on his watch. It's not connected with politics; it's just been in my view a lax effort. They just have not been aggressive. It sort of fits with sort of a little bit of the Obama mentality of let's turn the page on torture, too. Let's just turn the page on what happened in the past.
So I think he does have something to answer for there, and the Congress blighting everything involving Dodd-Frank, that is a shared responsibility. One wishes, or I wish, Obama had taken more of a leadership role way back when he was fighting about healthcare and pushing that up to the fore, not just healthcare, which was then taken by his opponents and used to demonize him and help give him this Congress that he now has.
Tavis: How do you read, Frank, and I'm really curious as to your take on this, how do you read the fact that the Obama people have so badly missed focusing on jobs? This economy was taking. We were headed into recession during the debates he was having with John McCain.
I've said many times on this program and elsewhere between McCain and Obama, respectfully, the word "poverty" never came up one time. We could talk about the middle class; poverty never came up. It's a word he still doesn't want to utter to this day, the poor or poverty in this country.
But I'm just trying to figure out how a campaign, whether you like or loathe them, agree or disagree, a campaign that was so good on being focused, that was so good on staying on message, that was so good at messaging during the campaign could so badly miss the issue of jobs in this White House?
Rich: I couldn't agree with you more, and of course we don't know the answer, but there are several theories. One is that he was to some extent too much in the grip of people that he appointed, the sort of Robert Rubin retinue led by Timothy Geithner and Larry Summers. That was not that focused on jobs as the main thing.
So even in the stimulus, explicit plans to try to have a WPA jobs program, to put people directly to work, was, we now know, essentially shot down by the Geithner forces in the internal administration debate. This is an administration that took almost a year after Obama entered the White House to have any kind of even sort of pro-forma jobs council, which is just amazing, given the circumstances that you so accurately describe when he came in.
Then there was the healthcare focus and then what I don't understand – and this is really the hardest question to answer – is how Obama, after healthcare, sort of waltzed past jobs as a focus and segued into the Republican turf of deficit reduction, almost as if he was intimidated by the Tea Party, even though every poll by every major pollster from Inauguration Day to the present shows that jobs and unemployment is a much higher priority for most Americans than the deficit.
Tavis: Here's another question maybe you know the answer to, because I do not. There are those, including yours truly, who are hopeful that when the time came to reshape his economic team that maybe we'd get a new team of people in that might understand these issues a little bit better.
So when Goolsbee leaves, when Christina Romer leaves, when Larry Summers leaves, when Peter Orzag leaves, there is hope in the air, at least for that period of time, that this new economic team might get it. Maybe you see something that I don't.
But is there a new team in place that might come to understand these issues better, number one, and is there enough time between now and Election Day if they did understand and embrace these issues a little more differently?
Rich: All right, well, two questions. The first one is no, I don't see any change, and in fact you could argue that Goolsbee and Romer and Jared Bernstein, who's also gone, were all on the side that we think was important, on the side of pushing jobs, pushing more spending, a larger stimulus, more proactive job creation over the deficit.
They lost. They're gone. They are not, as far as I can tell, being replaced by people who are picking up that argument.
On the second point, yes, there's a long time between now and Election Day, particularly in American politics, where things can change in a week. If he were to seize it, starting with this fight over the debt ceiling that's going on now, and be strong and start to change his priorities, I think it could make a difference.
What you have to remember is some of the swing states that he won last time, like Florida, Nevada, North Carolina, they have higher, in some cases far higher, unemployment rates than even the miserable record in the rest of the country. So it's imperative that he do this, not only for the good of the country but also for his own political survival, I think.
Tavis: Now we circle back to your initial point, talking about political survival, your very first point about Obama versus Romney. If he, in fact, is the presumed or presumptive nominee of the Republican Party – that remains to be seen – but if it is –
Rich: Absolutely.
Tavis: If it is, in fact, Mitt Romney, how is Obama going to run best against him on these issues?
Rich: Well, I think Obama's got to smoke Romney out, because Romney's record is terrible. Do you know that when he was governor of Massachusetts, Massachusetts had the lowest rate of job creation except for one state, which was Louisiana, which had a huge exodus of the workforce because of Katrina? That's Romney's record.
Romney's record at Bain is one of downsizing companies. So he's got to smoke Romney out and challenge him, and he has to do it from a position of strength. Obama, as we were just saying, has to have his own record and a renewed vigor about this that can be a clear-cut alternative. He can't just be another sort of seemingly corporate guy running against another corporate guy.
Tavis: I hate to use these words, "change" and "hope," because they've been so overused in our lexicon over the last few years, but as I read the piece, Frank, there is a sense – I'm not suggesting you say this explicitly; maybe you do.
But there is a sense I get in reading your piece that you believe, as you've already said tonight, that one, there is time, but more than just time, you believe that Obama is still capable, that there's something still inside of him that you can connect to, that you can appeal to, those who agree with your point of view on this.
Something there that we can perhaps get the president to understand and respond. I raise that to ask why it is, if my read on that is right, why, then, are you hopeful? Where's the evidence of that? Do you think he's going to stand strong on the debt ceiling and not give them what they want on deficit reduction?
I'm just trying to get a sense of why you remain hopeful after all the words you used in this article.
Rich: (Laughs) Well, I may be just a fool to hold on to any hope. (Laughter) Tavis, I can't make – I don't have any great argument except a fundamental conviction, I guess, that this is a decent guy, much of whose record in history, including, by the way, as a community organizer, suggests that his overall passions are not the ones we're seeing presented and seeing so compromised in the past couple of years. I also feel he is somebody who when his back is against the wall tends to wake up and smell the coffee.
A third thing is in the press conference that he gave last week, where he was immediately, of course, insulted by the Republicans for being so out there and so angry when in fact all he did was fight a little and show some spine, and yet that even got him called a four-letter word on another network, that Obama, he's still there.
We've seen a little bit more of it this week, but we'll see. The history, unfortunately, has been he does this fitfully and then retreats. He called – not as a high point of his administration, but he called some of the bankers "fat cats" and then retreated from it three months later in 2009.
We have to hope that he'll stick to it. A lot's at stake for him as well as for America.
Tavis: I think you're right. The American people want to see somebody fight for them, and I'm just suggesting that now would be a good time to start if you want to get reelected.
Rich: You bet. (Laughter) You bet, you bet, and that really, that you have – I don't mean to pick on Mitt Romney, but let's do it, everyone else does. (Laughter) Look, he may not be the nominee, we don't know who the Republicans are going to nominate. But for now he actually pulled even to Obama in an important poll, the "Washington Post/ABC" poll.
Romney is the most transparent phony, and I think many Republicans would agree, that you can imagine. He's rolling up his shirtsleeves, he's letting a few pieces of hair fall out of place, a little bit less hair gel, and we're supposed to believe he's Tom Joad in "The Grapes of Wrath." That's how he's presenting himself.
Four years ago or three years ago he presented himself as a religious conservative. That didn't work. So that's really a paper tiger if Obama is going to be the real tiger.
Tavis: Frank Rich is back, and unapologetically. I am happy about that, as I'm sure many of you are. He's now writing for "New York" magazine. His first piece is out and it's a hot one. There'll be a lot of talk about this in the coming days and weeks. It's called "Something Rotten: Obama's Failure to Right the Wrongs of this Crash Has Haunted His Presidency and Could Undo It." Frank Rich, welcome back and good to see you, my friend.
Rich: Great to see you, my friend. Thanks for having me.
"Announcer:" Nationwide Insurance supports Tavis Smiley. With every question and every answer, Nationwide Insurance is proud to join Tavis in working to improve financial literacy and remove obstacles to economic empowerment one conversation at a time. Nationwide is on your side.
And by contributions to your PBS station from viewers like you. Thank you.
External Links


text: Hello, I'm a grad student at American University (Washington DC) making a film about lawn care in America. I would like to get some shots of lawn care companies or individuals applying fertilizer, pesticides, mulch, etc.. Do you have any advice as to the best approach to do that? I don't want to seem too intrusive but would like some close-up shots of spraying, seeding, etc. Would any of you be willing to let me film you doing that? You would remain strictly anonymous in the fil so there is no need to worry about privacy matters. I probably would be with you for thirty minutes and wouldn't interrupt your work. I live in the DC Metro area and am willing to drive wherever you are, within say 50 miles. Thanks in advance for your attention and help. And sorry for the odd question. Will


text:
GOALKEEPER Marian Kello has signed a new one-year contract with St Mirren, the Paisley club have confirmed.
Kello, 31, signed for Saints last October and made 24 appearances, recording six clean sheets in the process, and will be part of new manager Tommy Craig's plans until the summer of 2015.
Defender Mo Yaqub, 20, has also signed up for another year.
Mark Williams and Adam Brown have stepped up from the Academy to the first team squad having penned one-year deals and Declan Hughes also moves up having signed a contract until January 15, 2015.
Craig is delighted to retain the services of Slovakian international Kello.
He told the club's official website: "He had an impressive season right up until the last four or five weeks when he picked up an injury and we couldn't play him.
"Overall, he came here and impressed everyone at the club with his professionalism and his talent as a goalkeeper is there for everyone to see.
"To get him on board for another year is good news for me and the fans."
Craig claims there is nothing to report with regards Scotland Under-21 midfielder Kenny McLean, who has been linked with a move to Rangers, among others.
He said: "There's been no further movement on Kenny McLean, and everything else is as it was."


text:
TAKE ACTION! Tell the Department of Homeland Security to extend TPS for Haitians in the U.S.
May 16, 2017
In 2010 an earthquake left Haiti in disastrous conditions. An estimated 50,000 Haitians who were in the United States at the time were granted permission to remain and to work lawfully through temporary protected status (TPS). However, the Trump administration has indicated that there is a strong possibility that TPS may no longer be extended to Haitians living in the U.S.
Ending temporary protected status for Haitians would put thousands of people at risk for deportation.
The devastating effects of Hurricane Matthew in 2016 have made it difficult for Haiti to improve its infrastructure and living conditions. Just like the communities of Eastern North Carolina, Haiti is struggling to rebuild what was damaged and lost in that hurricane. With the cancelation of TPS, Haitians would be returning home to loss, poor conditions, unemployment, and uncertainty. If deported, they would also be leaving behind families and small children who would not be able to prosper on their own, many of whom are U.S. citizens.
Sending Haitians back now would be devastating for those who are working and contributing to life in the U.S., as well as a blow to aid agencies and the Haitian government who may be forced to contend with tens of thousands of additional people to incorporate into relief and recovery programs.
TAKE ACTION! Call the Department of Homeland Security Comment Line at 202-282-8495 and ask to extend TPS for Haitians in the U.S.


text: Date: Wed, 23 Mar 94 22:42 PST From: Matt Bailey <email@example.com> I like the proposal alot except can users be added by anyone other than root? like say if there was three admins can anyone add a user with out know the root passwd? No. root is still the only user that can add users. Ian Murdock <firstname.lastname@example.com>


text:
MINNEAPOLIS — With eight days remaining until the trade deadline, Nuggets coach Brian Shaw said he'll refrain from offering any input about what his franchise should or should not do.
"I think that with all that I'm dealing with in terms of coaching the team, I'm just going to concentrate on coaching the guys that are here and available to play," Shaw said. "That's on (general manager) Tim Connelly and (assistant general manager) Arturas (Karnisovas) and (team president) Josh (Kroenke) and those guys. I don't even try to pretend the numbers and the salary cap and restrictions that you have from doing this and doing that."
The Nuggets aren't likely to be overly active at the trade deadline anyway, beyond the expected dealing of disgruntled point guard Andre Miller. Injuries — and Miller's absence — have pared the Nuggets roster down to 10 active players, but they hope to get the services on injured guard Ty Lawson back soon after the All-Star break, as well as any individual brought over in a deal.
"I think this first year and where we are, my input wouldn't really make that much of a difference," Shaw said. "So I'm not really concerned about it. I think it's more important in the offseason that when the season is over, whenever that is, that I just weigh in and say 'This is what we need, in my opinion.'"
After the season, however, will be different.
"This year has been a year of discovery for me, especially because I've been in the East; I wasn't familiar with a lot of the players," Shaw said.
"And so just getting to know them and learn them this year. So now, having been around them and going through what we've gone through, I have a better understanding of who can get it done, who can't, who is durable, who is tough, who is not.
"So, going forward, I can say, okay well I know at this position we need more depth or we need more defensive minded perimeter guy to be able to guard these kinds of situations, whatever the case may be. And then going forward, now I've given some input. But still, it's not my money being spent.
"I've always said from Day One I really just want to be concerned about coaching. Whatever I'm given to work with, I'll work with and try to coach them up the best that I can."
Christopher Dempsey: firstname.lastname@example.com or twitter.com/dempseypost


text:
Nothing complements all your fun summer fashion better then a nice, bright white smile. I find that especially in the summer, when skin is a bit tanner and the clothes a bit brighter, a white smile is the perfect accessory. In the last few years lots of new over the counter products have come out for the everyday gal who can't afford in-office whiting. The GO SMILE Smile Whitening System is a product that has less sensitivity because the apply the product right on the teeth only. Although GO SMILE products tend to cost a bit more then the grocery store variety, they have been super successful and a good way to jump start your whitening efforts.
Of course when talking about teeth whitening, Crest has to be mentioned. In my mind they were one of the first companies to offer at home whitening at an affordable price. The latest product from them, 3D White Whitestrips Professional Effects, has a better sealed strip and is a once a day 30 minutes treatment.
If you don't want the time or the commitment of strips or other at home whitening, then maybe just ease into it with some whitening toothpaste. There are so many different types and brands of whitening toothpaste, it would be impossible to cover. So just head on down to your local store and pick the one you think you will like best, I really like ARM & HAMMER Advance White Brilliant Sparkle.
Enjoy the sun and show off those pearly whites!


text:
It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Is this a replica (see photo) of an ancient single-seat rocket-ship? That's what it looks like to Zecharia Sitchin, the leading authority and scholar on the Ancient Astronaut theory. Hidden away in the Istanbul Archaeology Museum in Turkey for a quarter of a century, Sitchin recently convinced the Museum that this artifact may indeed be ancient, and not the modern forgery they concluded it must be, simply because our current view of our ancient history doesn't include rocket-ships.
Originally posted by adeclerk
reply to post by Hardstepah
If you have any knowledge of history you would know that Danikens claims are unfalsifiable, and therefore ridiculous.
Originally posted by EvolEric
Come on dude! Prove that Daniken is wrong...
Originally posted by Wandering Scribe
I'm actually just seeing a bearded figure—possibly like a Gnome—lying on it's side, angled a tiny bit off true so that we can't get a perfect head-on view of it. I have to look very hard, and ignore much of the masonry present, to see a spaceship and occupant. Now, the rocket is from Turkey, just north of Iran/Iraq's Mesopotamian basin, which is just north-east of Kemet—Egypt—who had the bearded dwarf-god Bes. Bes was a bearded dwarf who protected children, fought demons, and overlooked childbirth. Not to say that the Istanbul Rocket IS Bes, but, religious syncretisism often allowed for cultural beliefs and values from one land to blend into others. Egypt deities are found in Mesopotamia, and vice-versa. So, it's possible depictions of Bes traveled North from Egypt as well, changing as they went.
As for the Ancient Astronaut theory, try out this link HERE. The entire project hasn't been translated to English yet, but, several of the more popular Ancient Astronaut images have been covered, and their cultural and artistic origins explained. The religions of man—except of course for the UFO cults, Cargo cults, and Scientology—are not alien in origin. They develop out of animism, shamanism, and evolve to include human philosophy and spirituality. Our deities are not space aliens. They are humans with animal images. Mesopotamia, Egypt, India, Greek polytheism, Norse and Icelandic paganism, early Christian demon and angel beliefs... all of them feature blends between human and animal; not human and alien.
So, while the "rocket" is an interesting find... it is nothing more than a bearded-drawf figure in my opinion. Another poster also said that it was not as ancient as the other relics recovered from the area. If that is true, than it also stands to debunk the rocket as a rocket.
~ Wandering Scribe


text:
Reader's Digest Asia posted this photo on its Facebook page:
The caption says, "In reply, my friend told me, "I held on so long, only to give up in the end so that I would remember the lesson learned." Dear friends, what do you think?"
This is my answer:
It depends on what you are holding on though. If it is something you want to achieve/reach, holding on may not be enough, you have to give it your best shot. If you fail once give it another try. Hold on 'til the end for every sunrise gives you an opportunity to get your heart's desire. If what you are holding on to, however, is a person or a relationship, it's not a question of whether to hold on or let go I guess. It's whether the person still wants you in his/her life. Sometimes, no matter how much we try to be a part of our special someone's life, he/she may be better off and happier without us in it. Not holding on doesn't mean we love less for letting go is a way of showing how great our love is that we would gladly embrace pain just to see them happy. Whichever, nonetheless, let's try not to lose sight of what we have while holding on to what we don't have 😀


text:
- Altman Easy Latch Kits
- Car Interior Products
- Clothing
- Door Lock Accessories
Never before has it been easier to upgrade your 1940-1966 classic truck's door latches. Trique Mfg. is the home of the Altman Easy Latch.
The Altman Easy Latch is the one and only complete bolt-in latch system for 1940-1956 Ford Trucks and 1947-1966 Chevy Trucks. The Altman Easy Latch is a vehicle specific bear jaw style latch system that allows you to keep your existing inside and outside door handles, as well as your outside lock cylinder. Each of our installation plates are contoured to match your door body lines and give you a nice factory finish once installed. There is no welding involved; simply make a small cut made in the corner of your door using the provided template, drill a few holes, and you will be on your way to opening and closing your doors with ease. The bear claw door latch system truly works to ensure that your doors will not only close properly, but stay closed and keep you safe.
Our Altman latches address the main problems found in many old classic trucks: the old car doors stick and are hard to open and sometimes (most of the time) you have to slam them to get them closed. Once you get them closed, do you feel like they are secure? Ever had your door fly open on you like the video above shows? Many people have. Our door latch system works more like a modern door latch. We have 3/16" case hardened steel paws that close around a stainless steel striker pin to ensure that your doors will not pop open when the body flexes. Each of our latches features a 2-position catch system to provide an extra level of safety. We designed these latches much like your classic truck was built...to last. The body and levers of our latch are zinc plated to provide corrosion protection, while our internal paws are case hardened and black oxide coated to resist abrasion. The internal springs and the striker pins are stainless steel and best of all, it is all made right here in the USA. No more foreign knock-offs of latches that were in need of help to begin with. Browse our line of Altman Latches and order a set today! You will be glad you did.
Stop slamming your doors—go easy with the Altman Easy Latch.